Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Indonesia Energy Corporation Limited (INDO) Price & Performance

Citius Pharmaceuticals IncTrade
Indonesia Energy Corporation LimitedTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Indonesia Energy Corporation Limited — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Indonesia Energy Corporation Limited trades at $2.91 (market cap $45.55M). The key difference: Indonesia Energy Corporation Limited is far larger — about 2.3× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

CTXRINDO
Market Cap
$20.01M$45.55M
Sector
HealthEnergy
52-Week High
$1.82$6.74
52-Week Low
$0.48$2.49
Enterprise Value
$16.23M$40.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.

The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.

Indonesia Energy Corporation Limited

INDO trades at $2.80 with a slight 0.72% daily gain. The technical picture is bearish with moving averages signaling caution, while fundamentals show significant challenges with negative profit margins (-253.4%) and weak revenue of $2M in 2025. Recent news highlights operational progress with drilling commencement at the K-29 well. Analyst consensus remains unanimously bullish with 3 buy ratings.

The outlook is speculative given deep losses, but drilling success could drive upside. Key risks include execution in exploration, sustained negative cash flow, and oil price volatility. The stock presents high-risk potential for investors betting on operational turnaround versus current financial distress.

Returns comparison

Trailing returns across standard periods

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Indonesia Energy Corporation Limited

Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.

Read more on INDO